Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury
By I. Edwards HealthDay Reporter
TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.
The company said the injury went away after the person stopped taking the drug, called danuglipron, The Associated Press reported.
The pill was in early testing to help determine the best dose, according to a Pfizer spokeswoman.
The company had planned to move the drug into late-stage trials, typically the final step before review by the U.S. Food and Drug Administration (FDA).
Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.
Obesity drugs have become a major focus for pharmaceutical companies. Injectable treatments like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy have brought in billions in revenue. Zepbound earned nearly $5 billion in 2024 alone, The Associated Press reported.
But these drugs must be injected, which some folks don't want to do.
As a result, drugmakers have been racing to develop pill versions. Lilly expects to release new data this year on two oral obesity drugs it is studying.
While demand for these treatments is high, access has been an issue. Some patients face insurance issues or high out-of-pocket costs.
Even with recent price cuts, many of these medications still cost hundreds of dollars per month.
Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.
Sources
- The Associated Press, April 14, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
FDA Warns of Unapproved Hair-Loss Product Linked to Side Effects
THURSDAY, April 24, 2025 — A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left them battling sexual...
U.S. Births Barely Rise in 2024
THURSDAY, April 24, 2025 (Health Day News) — Fewer babies are being born in the U.S., and experts are worried what that portends for the future. The number of babies born...
Cancer Prevention Not Yet Recovered From Pandemic-Era Declines, Report Says
THURSDAY, April 24, 2025 -- The effects of COVID-19 continue to reverberate in the cancer risk factors of Americans, a new American Cancer Society (ACS) study says. Screening for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.